Related Research Articles
The Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company, with partial American and British roots. It is the third largest pharmaceutical company in Asia, behind Sinopharm and Shanghai Pharmaceuticals, and one of the top 20 largest pharmaceutical companies in the world by revenue. The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year. The company is focused on oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies and vaccines. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States. As of 2015, Christophe Weber was appointed as the CEO and president of Takeda.
BioMed Central (BMC) is a United Kingdom-based, for-profit scientific open access publisher that produces over 250 scientific journals. All its journals are published online only. BioMed Central describes itself as the first and largest open access science publisher. It was founded in 2000 and has been owned by Springer, now Springer Nature, since 2008.
Human genetic enhancement or human genetic engineering refers to human enhancement by means of a genetic modification. This could be done in order to cure diseases, prevent the possibility of getting a particular disease, to improve athlete performance in sporting events, or to change physical appearance, metabolism, and even improve physical capabilities and mental faculties such as memory and intelligence. These genetic enhancements may or may not be done in such a way that the change is heritable.
Annual Reviews is an independent, non-profit academic publishing company based in San Mateo, California. As of 2021, it publishes 51 journals of review articles and Knowable Magazine, covering the fields of life, biomedical, physical, and social sciences. Review articles are usually "peer-invited" solicited submissions, often planned one to two years in advance, which go through a peer-review process. The organizational structure has three levels: a volunteer board of directors, editorial committees of experts for each journal, and paid employees.
Maxygen Inc. was a biopharmaceutical company focused on developing improved versions of protein drugs using DNA shuffling and other protein modification technologies. The company was headquartered in Redwood City, CA. It dissolved in 2013. The Maxygen legacy was revived in 2018 with a focus on Directed Evolution of Proteins using Molecular Breeding. Maxygen LLC is currently headquartered in Sunnyvale, CA.
The Journal of Alternative and Complementary Medicine is a monthly peer-reviewed medical journal covering alternative medicine published by Mary Ann Liebert. It was established in 1995 and is the official journal of the Society for Acupuncture Research. The editor-in-chief is John Weeks, who succeeded the founding editor, Kim A. Jobst.
Election Law Journal: Rules, Politics, and Policy is a quarterly peer-reviewed law journal published by Mary Ann Liebert, Inc. covering legal issues related to elections and voting rights. It was established in 2002 with Daniel H. Lowenstein and Richard L. Hasen as founding editors-in-chief. As of 2010, the editors are Daniel P. Tokaji and Paul Gronke. As of 2018, the Editor-in-Chief is David Canon, University of Wisconsin-Madison. Election Law Journal is abstracted and indexed in Westlaw and International Political Science Abstracts/Documentation Politique Internationale.
The American Thyroid Association (ATA) is a professional organization of over 1700 medical specialists devoted to thyroid biology and to the prevention and treatment of thyroid disease through excellence in research, clinical care, education, and public health. The ATA publishes the journals Clinical Thyroidology for the Public and Signal. The peer-reviewed journals Thyroid, Clinical Thyroidology and VideoEndocrinology are published through Mary Ann Liebert, Inc., publishers.
Tissue Engineering and Regenerative Medicine International Society is an international learned society dedicated to tissue engineering and regenerative medicine.
Frontiers Media SA is a publisher of peer-reviewed, open access, scientific journals currently active in science, technology, and medicine. It was founded in 2007 by Kamila and Henry Markram. Frontiers is based in Lausanne, Switzerland, with other offices in the United Kingdom, Spain, and China. In 2022, Frontiers employed more than 1,400 people, across 14 countries. All Frontiers journals are published under a Creative Commons Attribution License.
The Journal of Neurotrauma is a monthly peer-reviewed medical journal covering research on neurotraumas. It is an official journal of the National Neurotrauma Society and the International Neurotrauma Society. The journal was established in 1984 and is published by Mary Ann Liebert, Inc. The editor-in-chief is David L. Brody, MD, PhD.
Genetic Testing and Molecular Biomarkers is a monthly peer reviewed scientific journal published by Mary Ann Liebert, Inc. The editor-in-chief is Garth Ehrlichs. The journal covers genetic testing research along with associated ethical, legal, social, and economic issues. Related genetic testing coverage includes risk assessment, genetic counseling, carrier detection, novel instrumentation, and cytogenetics. It is the official journal of Genetic Alliance.
The Journal of Women's Health is a monthly peer-reviewed healthcare journal focusing on women's health care, including advancements in diagnostic procedures, therapeutic protocols for the management of diseases, and research in gender-based biology that impacts patient care and treatment. The journal was established in 1992 and is published by Mary Ann Liebert, Inc. The editor-in-chief is Susan G. Kornstein. It is the official journal of the Academy of Women's Health and the American Medical Women's Association.
Editas Medicine, Inc.,, is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.
LGBT Health is a bimonthly peer-reviewed academic journal covering healthcare as it relates to LGBT individuals, the only peer-reviewed journal of its kind. It was established in 2014 and is published by Mary Ann Liebert, Inc. The editor-in-chief is William Byne. According to the Journal Citation Reports, the journal has a 2017 impact factor of 2.514.
Population Health Management is a bimonthly peer-reviewed public health journal covering the study of population health, and how it can be improved by improving health care services. It was established in 1998 as Disease Management, obtaining its current name in 2008; the journal's first issue under its current name was published in August 2008. It is published by Mary Ann Liebert, Inc. and the editor-in-chief is David B. Nash. According to the Journal Citation Reports, the journal has a 2020 impact factor of 2.459.
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.
The He Jiankui affair is a scientific and bioethical controversy concerning the use of genome editing following its first use on humans by Chinese scientist He Jiankui, who edited the genomes of human embryos in 2018. He became widely known on 26 November 2018 after he announced that he had created the first human genetically edited babies. He was listed in the Time's 100 most influential people of 2019. The affair led to ethical and legal controversies, resulting in the indictment of He and two of his collaborators, Zhang Renli and Qin Jinzhou. He eventually received widespread international condemnation.
The CRISPR Journal is a peer-reviewed scientific journal published every two months by Mary Ann Liebert. It covers research on all aspects of CRISPR research, including its uses in synthetic biology and genome editing. Its editor-in-chief is Rodolphe Barrangou. The journal's editorial board includes key pioneers of CRISPR technology Jennifer Doudna, Emmanuelle Charpentier, and George Church. The inaugural issue of the journal was published in February, 2018.
Transgender Health is a bimonthly peer-reviewed academic journal covering transgender health. It was established in 2016 and is published by Mary Ann Liebert. The editor-in-chief is Robert Garofalo.
References
- 1 2 3 4 5 6 7 8 9 10 Worley, Dwight R. (23 July 2000). "Genetic Genius - Part 1". Business. The Journal News. White Plains, New York: Gannett. pp. 1, 2–D. Retrieved 31 July 2018– via Newspapers.com.
- ↑ McElroy, Emily; Kubilius, Ramune (2003). "An Interview with Mary Ann Liebert and Tom Mulak" (PDF). Serials Review. 29 (2): 137–143. doi:10.1016/S0098-7913(03)00033-9. S2CID 62532552. Archived from the original (PDF) on 17 March 2006.
- 1 2 "Company Overview of Mary Ann Liebert, Inc". www.bloomberg.com. Retrieved 2018-08-01.
- ↑ Lancaster, Hal (6 August 1995). "Some people are born to be entrepreneurs". Wisconsin State Journal (Reprint from Wall Street Journal). Madison, Wisconsin. p. 1H. Retrieved July 31, 2018– via Newspapers.com.
- ↑ Liebert, Mary Ann. "Genetic Genius - Part 2". Business. White Plains, New York: Gannett. Retrieved 2024-02-24– via Newspapers.com.
- ↑ "Publication List A - Z". Mary Ann Liebert.
- ↑ "Mary Ann Liebert, Inc. | Home". Liebertpub.com. Retrieved 2023-10-02.
- ↑ "The CRISPR Journal, a new peer-reviewed publication launching in 2018". EurekAlert!. Retrieved 2018-03-04.
